Merck KGaA Stepping Up In India, Eyes On Bavencio Trajectory
Executive Summary
Anandram Narasimhan, managing director of Merck Specialities Pvt. Ltd. in India, share insights on the uptick in the fertility business and the promise of new launches, including of the checkpoint inhibitor Bavencio, in the country. Overall, the “signs are good”, the executive tells Scrip in an interview.
You may also be interested in...
Merck Life Execs On APAC Firms' mRNA Tech Readiness, Start-Ups And AI
Merck Life Science’s top executives in India tell Scrip how they are helping biologics companies in APAC on their mRNA therapy journey. In the wide-ranging discussion, use of AI, the startup environment for biotechs and the changing face of manufacturing in India also came up.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.
India Biosimilar Cetuximab Go-Ahead: Merck KGaA Wants Data In Public Domain
Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.